Trading

Data

Solutions

Insights

Graybug Vision Stock

graybug.comHealthcareFounded: 2011Funding to Date: $160.77MM

Graybug Vision is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve.

Learn more about Graybug Vision IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

View Enterprise Value for Graybug Vision.

Register Today

Team

Management Team

Dan Salain

Chief Operating Officer

Charles Semba MD

Chief Medical Officer

Frédéric Guerard

Chief Executive Officer & Board Member

Peter Campochiaro MD

Co-Founder

Justin Hanes Ph.D

Co-Founder & Board Member

Pamela Wapnick

Chief Financial Officer

Peter McDonnell MD

Co-Founder

Board Members

Chau Khuong

OrbiMed

Hansoo Keyoung

Cameron Wheeler Ph.D

Deerfield Management

Gerald Cagle Ph.D

Christy Shaffer Ph.D

Emmett Cunningham Ph.D

Clarus Ventures

Frédéric Guerard

Justin Hanes Ph.D

Other companies like Graybug Vision in the Healthcare sector

Neuralink

Sector

Healthcare

Last Round Est. Valuation

$2.15B

Sector

Sector

Last Round Est. Valuation

$3.67B

Synchron

Sector

Healthcare

Last Round Est. Valuation

$400.53MM

Grail

Sector

Healthcare

Last Round Est. Valuation

$4.26B

Sector

Sector

Last Round Est. Valuation

$1.08B

Cytonics

Sector

Healthcare

Precision Neuroscience

Sector

Healthcare

News

Business Wire 08/20/2019

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases includin

Popular Topics

Popular Topics

Graybug Vision Stock

Register for Details